Abstract 371P
Background
Head and neck cancers (HNCs) are a challenging disease to treat due to their anatomical complexity and high propensity for locoregional recurrence. Radiation therapy is a crucial component of treatment approach for HNCs. However, assessing the response to therapy can be difficult, particularly in the early post-treatment period. Positron emission tomography (PET) with the glucose analogue [18F] fluorodeoxyglucose (FDG) has shown promising results in the assessment of treatment response in HNCs. Therefore, this systematic review is written to evaluate the role of FDG-PET/CT in the assessment of response to radiotherapy in HNCs.
Methods
A comprehensive search of electronic databases was conducted, including EMBASE, Scopus, Pubmed, PMC, and Science Direct from inception to April 2023. Studies were included if they reported on the use of FDG-PET/CT for assessing treatment response in HNCs treated with radiation therapy. Quality assessment using Newcastle-Ottawa Scale and data extraction were performed independently by three reviewers.
Results
16 studies reporting on a total of 348 patients were included in this analysis. The data assessed in the included studies were diverse, including the evaluation of the diagnostic performance of FDG-PET/CT, the comparison with conventional imaging techniques, the ability to avoid neck dissections, or assessed which patient population would derive most benefit from post-treatment FDG-PET/CT scan. Despite their diversity, almost all studies have showed that FDG-PET/CT scan is a reliable method to evaluate residual or recurrent tumour within 6 months post-(chemo)radiation therapy with pooled sensitivity of 84% and pooled specificity of 90%. There was a moderate risk of bias due to selection bias. Also, confirmation of positive nodal disease at the time of diagnosis and prior to therapy is an important shortcoming in most included studies.
Conclusions
FDG-PET/CT within 6 months after (chemo)radiotherapy in HNCs patients is a reliable method for ruling out residual/recurrent nodal disease and obviates the need for therapeutic intervention. However, further standardization of the PET technique is required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract